Seres Therapeutics (MCRB) Total Non-Current Liabilities (2017 - 2025)
Historic Total Non-Current Liabilities for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $97.8 million.
- Seres Therapeutics' Total Non-Current Liabilities fell 3612.0% to $97.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.8 million, marking a year-over-year decrease of 3612.0%. This contributed to the annual value of $124.2 million for FY2024, which is 6909.42% down from last year.
- Seres Therapeutics' Total Non-Current Liabilities amounted to $97.8 million in Q3 2025, which was down 3612.0% from $108.9 million recorded in Q2 2025.
- Seres Therapeutics' 5-year Total Non-Current Liabilities high stood at $407.1 million for Q2 2024, and its period low was $97.8 million during Q3 2025.
- Its 5-year average for Total Non-Current Liabilities is $247.4 million, with a median of $235.0 million in 2022.
- Per our database at Business Quant, Seres Therapeutics' Total Non-Current Liabilities soared by 5886.14% in 2022 and then plummeted by 7324.92% in 2025.
- Over the past 5 years, Seres Therapeutics' Total Non-Current Liabilities (Quarter) stood at $211.9 million in 2021, then surged by 58.86% to $336.6 million in 2022, then rose by 19.39% to $401.8 million in 2023, then tumbled by 69.09% to $124.2 million in 2024, then fell by 21.28% to $97.8 million in 2025.
- Its last three reported values are $97.8 million in Q3 2025, $108.9 million for Q2 2025, and $111.8 million during Q1 2025.